Skip to main content
Clinical Trials/NCT05268770
NCT05268770
Unknown
Not Applicable

The Role of Inflammation in the Pathogenesis of Tinnitus

University Medical Center Groningen0 sites100 target enrollmentMarch 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tinnitus, Subjective
Sponsor
University Medical Center Groningen
Enrollment
100
Primary Endpoint
Tinnitus vs no tinnitus
Last Updated
4 years ago

Overview

Brief Summary

Rationale: Tinnitus is the perception of sound without an external source. In the past decade, inflammation has been implicated in the pathophysiology of tinnitus. In animal models of tinnitus, the expression of proinflammatory cytokines Tumor Necrosis Factor-α (TNF-α) and interleukine-1β (IL-1β) was increased throughout the whole auditory tract. Only two studies evaluated cytokine concentrations in tinnitus patients. In these studies an increase of IL-6 and decrease of IL-10 have been objectified. However, studies did not include tinnitus patients based on the degree of hearing loss, despite that inflammation has also been implicated in hearing loss. On the other hand, studies about inflammation in hearing loss did not (always) exclude tinnitus. Thus, it remains unclear whether the upregulated cytokine concentrations the studies are specific for tinnitus, and whether potential effects remained unsignificant because the presence of hearing loss is a confounder. Therefore, the aim of this study is to evaluate the presence of inflammation in tinnitus patients with normal hearing.

Objective: The main objective is to evaluate the presence of inflammation in blood samples of human subjects with tinnitus and normal hearing, compared to healthy controls. The secondary objective is to evaluate the relation between tinnitus severity and inflammatory marker concentrations.

Study design: This is a cross-sectional study.

Study population: Patients who have been referred to the tinnitus consultation at the outpatient clinic will be asked to participate in this study. For the control group, healthy volunteers will be recruited.

Main study parameters/endpoints: The main study parameter is the disparity in blood cytokine levels between participants with and without tinnitus. Secondary study parameters are the relation between tinnitus severity and blood cytokine concentration, and the difference in complete blood count measures in participants with and without tinnitus.

Registry
clinicaltrials.gov
Start Date
March 2022
End Date
August 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • To be eligible to participate in this study, a subject must meet all of the following criteria:
  • Adult, aged 18 years or older;
  • Hearing threshold: average of 1000kHz, 2000kHz \& 4000kHz ≤ 25 dB.
  • Anxiety score HADS ≤ 7
  • Depression score HADS ≤ 7
  • Participant has sufficient mastery of the Dutch language to fill out the questionnaires.
  • Psychosocially, mentally, and physically able to fully comply with this protocol.

Exclusion Criteria

  • Objective tinnitus.
  • Presence of neurological disease (apart from tinnitus)
  • Presence of inflammatory disease, or the use of anti-inflammatory medication.
  • Presence or history of a malignancy
  • Presence of a disease of the ear (e.g. chronic otitis media, otosclerosis, previous surgery etc).
  • Presence of an coagulation disorder
  • Presence of a serious psychiatric disorder.
  • Pregnancy

Outcomes

Primary Outcomes

Tinnitus vs no tinnitus

Time Frame: September 2022

Difference in cytokine levels between participants with and without tinnitus

Secondary Outcomes

  • Tinnitus severity(September 2022)

Similar Trials